Paper · 39875570

FGF-based drug discovery: advances and challenges.

Chen G and 3 others. Nat Rev Drug Discov, 2025. Cited by 38 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. FGF-based drug discovery: advances and challenges. Papers, record 39875570. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39875570

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: FGF-based drug discovery: advances and challenges.; PubMed
Journal: Nat Rev Drug Discov; PubMed
Year: 2025; PubMed
Publication types: Journal Article, Review, Research Support, Non-U.S. Gov't; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/39875570/; PubMed
DOI: https://doi.org/10.1038/s41573-024-01125-w; PubMed
The journal: https://conductscience.org/library/journal-index/101124171; PubMed
Citations, by iCite: 38; iCite
Relative citation ratio, by iCite: 10.02, provisional; iCite
Revised in PubMed: 2026-11-03; PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Chen G	Gaozhi
2	Chen L	Lingfeng	https://orcid.org/0000-0003-0089-6559
3	Li X	Xiaokun	https://orcid.org/0000-0002-6556-6262
4	Mohammadi M	Moosa	https://orcid.org/0000-0003-2434-9437

Source PubMed

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Fibroblast Growth Factors	Major topic
Drug Discovery	Major topic
Humans
Animals
Signal Transduction

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References328

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	36,644,237	A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.	JHEP Rep	2023	https://conductscience.org/library/papers/36644237	PubMed
2	10,490,103	Structural basis for FGF receptor dimerization and activation.	Cell	1999	https://conductscience.org/library/papers/10490103	PubMed
3	16,597,617	Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family.	J Biol Chem	2006	https://conductscience.org/library/papers/16597617	PubMed
4	20,685,823	PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop.	Am J Physiol Renal Physiol	2010	https://conductscience.org/library/papers/20685823	PubMed
5	19,755,711	Differential interactions of FGFs with heparan sulfate control gradient formation and branching morphogenesis.	Sci Signal	2009	https://conductscience.org/library/papers/19755711	PubMed
6	36,576,203	Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney disease.	Drug Deliv	2023	https://conductscience.org/library/papers/36576203	PubMed
7	31,743,079	Regulation and Effects of FGF23 in Chronic Kidney Disease.	Annu Rev Physiol	2020	https://conductscience.org/library/papers/31743079	PubMed
8	37,732,990	A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis.	Hepatology	2024	https://conductscience.org/library/papers/37732990	PubMed
9	29,654,817	Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis.	J Hepatol	2018	https://conductscience.org/library/papers/29654817	PubMed
10	31,104,833	Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.	Lancet	2019	https://conductscience.org/library/papers/31104833	PubMed

1 to 10 of 328

See all 328 references

Cited by30

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 38 citations.

PMID	Title	Journal	Year	In Papers	Source
42,875,754	FGFR pathway inhibition enhances PD-1 blockade and modulates antitumor immunity in colorectal cancer models.	BMC Cancer	2026	https://conductscience.org/library/papers/42875754	PubMed
42,871,852	Network Biology: Current Status, Applications, Challenges, and Future Prospects.	MedComm (2020)	2026	https://conductscience.org/library/papers/42871852	PubMed
42,793,070	State-Dependent FGF Signaling in Satellite Cell-Mediated Skeletal Muscle Regeneration and Pathological Remodeling.	Biomolecules	2026	https://conductscience.org/library/papers/42793070	PubMed
42,690,514	Fibroblast growth factors in Alzheimer's Disease pathogenesis: neuropharmacological implications for neuroprotection, neurogenesis, and therapeutic development.	Mol Biol Rep	2026	https://conductscience.org/library/papers/42690514	PubMed
42,675,086	Discovery of a covalent FGFR2-selective inhibitor overcoming clinically-acquired resistance mutations.	Nat Commun	2026	https://conductscience.org/library/papers/42675086	PubMed
42,657,105	Blood and lymphatic vascular remodeling in intervertebral disc degeneration.	Front Immunol	2026	https://conductscience.org/library/papers/42657105	PubMed
42,633,326	Advances in FGF/FGFR Signaling: Implications for Disease and Therapy.	MedComm (2020)	2026	https://conductscience.org/library/papers/42633326	PubMed
42,627,293	Application and Single-Cell Regulation Mechanism of Engineered EVs Combined With 4D-Printed Hydrogel for Infected Burn Repair.	Adv Sci (Weinh)	2026	https://conductscience.org/library/papers/42627293	PubMed
42,547,441	[Bidirectional two-sample MR analysis of causal relationships between human inflammatory proteins and HS and keloids].	Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi	2026	https://conductscience.org/library/papers/42547441	PubMed
42,544,926	FGF8 alleviates LPS-induced acute lung injury via the PPARγ/ERK1/2 signalling pathway in mice.	Ann Med	2026	https://conductscience.org/library/papers/42544926	PubMed

1 to 10 of 30

See all 30 cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
FGF19	9,965	PubTator's text mining	https://conductscience.org/library/genes/9965	NCBI Gene
FGF21	26,291	PubTator's text mining	https://conductscience.org/library/genes/26291	NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39875570

GET https://conductscience.org/api/papers/v1/39875570/references?page=2

API reference For AI assistants